Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−3.31 USD
−38.99 M USD
0.00 USD
32.11 M
About Soleno Therapeutics, Inc.
Sector
CEO
Anish Bhatnagar
Headquarters
Redwood City
Website
Founded
1999
FIGI
BBG0024L5B86
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of SLNO is 57.22 USD — it has increased by 5.77% in the past 24 hours. Watch Soleno Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Soleno Therapeutics, Inc. stocks are traded under the ticker SLNO.
SLNO stock has risen by 6.53% compared to the previous week, the month change is a 8.49% rise, over the last year Soleno Therapeutics, Inc. has showed a 102.55% increase.
We've gathered analysts' opinions on Soleno Therapeutics, Inc. future price: according to them, SLNO price has a max estimate of 93.00 USD and a min estimate of 67.00 USD. Watch SLNO chart and read a more detailed Soleno Therapeutics, Inc. stock forecast: see what analysts think of Soleno Therapeutics, Inc. and suggest that you do with its stocks.
SLNO reached its all-time high on Mar 4, 2015 with the price of 742.50 USD, and its all-time low was 0.85 USD and was reached on Dec 15, 2022. View more price dynamics on SLNO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
SLNO stock is 6.84% volatile and has beta coefficient of 1.26. Track Soleno Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Soleno Therapeutics, Inc. there?
Today Soleno Therapeutics, Inc. has the market capitalization of 2.49 B, it has increased by 5.46% over the last week.
Yes, you can track Soleno Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Soleno Therapeutics, Inc. is going to release the next earnings report on Mar 25, 2025. Keep track of upcoming events with our Earnings Calendar.
SLNO earnings for the last quarter are −1.83 USD per share, whereas the estimation was −0.60 USD resulting in a −202.48% surprise. The estimated earnings for the next quarter are −1.03 USD per share. See more details about Soleno Therapeutics, Inc. earnings.
Soleno Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
SLNO net income for the last quarter is −76.62 M USD, while the quarter before that showed −21.85 M USD of net income which accounts for −250.58% change. Track more Soleno Therapeutics, Inc. financial stats to get the full picture.
No, SLNO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 26, 2024, the company has 42.00 employees. See our rating of the largest employees — is Soleno Therapeutics, Inc. on this list?
Like other stocks, SLNO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Soleno Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Soleno Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Soleno Therapeutics, Inc. stock shows the buy signal. See more of Soleno Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.